摘要
目的:观察多西他赛联合表柔比星的新辅助化疗(NCT)方案在中晚期乳腺癌治疗中的疗效及毒副反应。方法:选择我院乳腺外科治疗的中晚期乳腺癌患者40例。所有患者接受多西他赛75mg/m2和表柔比星75mg/m2,静脉滴入1d。每21d为1个周期,行3~5周期后评价疗效和毒副反应。结果:(1)RR为87.50%,其中CR为40.00%,PR为47.50%。(2)不良反应主要以脱发(100.00%)、白细胞减少(92.50%)及胃肠道不适(60.00%)多见,其他均有不同程度的血小板下降(47.50%)、心脏毒性(27.50%)及口腔黏膜炎(17.50%)。结论:多西他赛联合表柔比星对中晚期乳腺癌进行NCT,有效率高,治疗耐受性好,值得临床推广运用。
Objective :To observe the effects and adverse reactions of Neoadjuvant Chemothempy (NCT ) with Docetax-el plus Epirubicin in patients with advanced breast cancer .Methods:40 patients with advanced breast cancer are treated in the department of breast surgery .All patients are treated with Docetaxel 75mg/m2 and Epirubicin 75mg/m2 intrave-nously guttae on 1d .It is going to evaluate the effects and adverse reactions after 3 to 5 periods which are 21 days .Re-sults :The overall response rate(ORR) was 87 .50% ,the complete response(CR) was 40 .00% ,and the partial response (PR) was 47 .50% .The major adverse reactions were alopecia(100 .00% ) ,leukopenia(92 .50% ) ,gastrointestinal reac-tions(60 .00% ) ,thrombocytopenia (47 .50% ) ,cardiac toxicity (27 .50% ) ,and stomatitis (17 .50% ) .Conclusion:It is high efficiency and well tolerated for patients with advanced breast cancer which Docetaxel plus Epirubicin is used to do the Neoadjuvant Chemothempy .It is worthy of clinical promotion .
出处
《医学理论与实践》
2014年第15期1973-1974,1977,共3页
The Journal of Medical Theory and Practice
关键词
乳腺肿瘤
中晚期
新辅助化疗
多西他赛
表柔比星
Breast cancer,Advanced stage,Neoadjuvant Chemothempy,Docetaxel,Epirubicin
